Search
SOLACI Congress
Institutional NewsPharmacologyAntiplatelet

Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome

solaci
solaci
309
0

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
In Search of the Optimal Depth for Self-Expandable Valves
Next article
Cardiovascular Sequelae Associated with COVID-19
solaci
solaci

More articles by this author

SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Dr. Omar Tupayachi - 0
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

Dr. Omar Tupayachi - 0
After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

Dr. Omar Tupayachi - 0
LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Institutional News

SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Dr. Juan Manuel Pérez - 0
Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Dr. Juan Manuel Pérez - 0
Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Dr. Omar Tupayachi - 0
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Dr. Juan Manuel Pérez - 0
Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Dr. Juan Manuel Pérez - 0
Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Dr. Omar Tupayachi - 0
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

Institutional News

SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives...

SOL SOLACI performed a new procedure in Argentina using bioabsorbable stents in pulmonary branches

solaci - 0
The SOLACI Solidarity Program carried out a new procedure on a patient from the region of Frías, in Santiago del Estero (Argentina), during October...

Venezuela 2025 Sessions | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submissions LIII SOLACI Regional Sessions – 18th Andean Region We invite all young Latin American cardiologists to submit clinically relevant interventional cardiology cases...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy